Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy.

ABSTRACT: Preclinical studies, in vivo, and in vitro studies, in combination with mathematical modeling can help optimize and guide the design of clinical trials. The design and optimization of alpha-particle emitter radiopharmaceutical therapy (αRPT) is especially important as αRPT has the potential for high efficacy but also high toxicity. We have developed a mathematical model that may be used to identify trial design parameters that will have the greatest impact on outcome. The model combines Gompertzian tumor growth with antibody-mediated pharmacokinetics and radiation-induced cell killing. It was validated using preclinical experimental data of antibody-mediated 213Bi and 225Ac delivery in a metastatic transgenic breast cancer model. In modeling simulations, tumor cell doubling time, administe

SUBMITTER: Karimian A 

PROVIDER: S-EPMC7024673 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature